Drug intelligence / Profile preview

KACM001 autologous lymphocyte injection

Development stage: Unknown
Lead developer: Beijing Biohealthcare Biotechnology
Modality: Cell Therapies
Administration: Intravenous

Overview

KACM001 is an autologous lymphocyte injection developed by Beijing Kangai Ruihao Biotechnology. It is a cell-based immunotherapy currently in Phase I/II clinical development in China. The therapy involves the ex vivo expansion and activation of a patient's own lymphocytes, which are then re-infused to target and eliminate cancer cells. It is primarily being investigated for the treatment of advanced, HER2-negative gastric adenocarcinoma in combination with standard-of-care chemotherapy regimens, such as S-1 plus oxaliplatin or cisplatin, for previously untreated locally advanced unresectable or metastatic disease.

Other names: KACM001KACM-001KACM 001autologous lymphocyte injection

Beyond the preview

Go deeper on KACM001 autologous lymphocyte injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KACM001 autologous lymphocyte injection.

Explore the full profile